Metabolic Abnormalities in Children With Epilepsy

Learn more about:
Related Clinical Trial
Tricaprilin Infantile Spasms Pilot Study Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm Sabril Patient Registry Epilepsy Phenome/Genome Project Metabolic Abnormalities in Children With Epilepsy Genetics of Severe Early Onset Epilepsies A Novel Approach to Infantile Spasms Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile Spasms Prednisolone in Infantile Spasms- High Dose Versus Usual Dose Addition of Pyridoxine to Prednisolone in Infantile Spasms Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) Open-label Extension to Protocol 1042-0500 Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH) Evaluation of Neuroinflammation in Children With Infantile Spasms Molecular Genetics in Infantile Spasms Genetic Studies in Patients and Families With Infantile Spasms Use of the Modified Atkins Diet in Infantile Spasms Treatment of Refractory Infantile Spasms With Fenfluramine A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

Brief Title

Metabolic Abnormalities in Children With Epilepsy

Official Title

Natural History of Metabolic Abnormalities in Children With Epilepsy

Brief Summary

      This study is designed to use positron emission tomography to measure brain energy use.
      Positron Emission Tomography (PET) is a technique used to investigate the functional activity
      of the brain. The PET technique allows doctors to study the normal processes of the brain
      (central nervous system) of normal individuals and patients with neurologic illnesses without
      physical / structural damage to the brain.

      When a region of the brain is active, it uses more fuel in the form of oxygen and sugar
      (glucose). As the brain uses more fuel it produces more waste products, carbon dioxide and
      water. Blood carries fuel to the brain and waste products away from the brain. As brain
      activity increases blood flow to and from the area of activity increases also.

      Researchers can label a sugar with a small radioactive molecule called FDG
      (fluorodeoxyglucose). As areas of the brain use more sugar the PET scan will detect the FDG
      and show the areas of the brain that are active. By using this technique researchers hope to
      answer the following questions;

      4. Are changes in brain energy use (metabolism) present early in the course of epilepsy

      5. Do changes in brain metabolism match the severity of patient's seizures

      6. Do changes in metabolism occur over time or in response to drug therapy
    

Detailed Description

      We propose to study children with recent onset partial epilepsy, cryptogenic infantile
      spasms, and idiopathic Lennox-Gastaut Syndrome with serial FDG-PET to elucidate the natural
      history and evolution of metabolic abnormalities associated with such epilepsies. The
      severity of the seizure disorder, and cognitive impairment, when present, will be correlated
      with the presence and extent of focal and global cerebral metabolic abnormalities.
    


Study Type

Observational




Condition

Generalized Epilepsy

Intervention

18 FDG


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

80

Start Date

April 1992

Completion Date

June 2004


Eligibility Criteria

        INCLUSION CRITERIA:

        Patients with partial seizures, infantile spasms and Lennox-Gastaut syndrome will be
        selected.

        EXCLUSION CRITERIA:

        Evidence of a structural lesion as cause for epilepsy.

        Degenerative or metabolic disease.

        Inability to comply with the protocol.
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00001325

Organization ID

920175

Secondary IDs

92-N-0175


Study Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)


Study Sponsor

, , 


Verification Date

June 2004